ImmuCell Reports Financial Condition on Feb 27, 2024
Ticker: ICCC · Form: 8-K · Filed: Feb 27, 2024 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**ImmuCell just dropped an 8-K on Feb 27, 2024, updating its financial results, so keep an eye on their performance.**
AI Summary
ImmuCell Corporation filed an 8-K on February 27, 2024, to report on its results of operations and financial condition. The filing indicates that the company, based in Portland, Maine, with IRS Employer Identification No. 01-0382980, is providing an update on its financial performance. This report is filed under the Securities Exchange Act of 1934, with a Commission File Number of 001-12934.
Why It Matters
This filing provides investors with an update on ImmuCell's financial health and operational performance, which can influence investment decisions and market perception.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and results of operations, not indicating any immediate high-risk events.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- February 27, 2024 (date) — Date of earliest event reported
- 001-12934 (other) — Commission File Number
- 01-0382980 (other) — IRS Employer Identification No.
- Portland, Maine (other) — Principal executive offices location
FAQ
What is the purpose of this 8-K filing by ImmuCell Corporation?
The 8-K filing by ImmuCell Corporation is to report on its results of operations and financial condition, as per Item 2.02 and Item 9.01 of Form 8-K.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 27, 2024.
What is the business address of ImmuCell Corporation?
The business address of ImmuCell Corporation is 56 Evergreen Drive, Portland, Maine 04103.
What is ImmuCell Corporation's Commission File Number?
ImmuCell Corporation's Commission File Number is 001-12934.
Under which act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-02-27 16:05:29
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC Nasdaq I
Filing Documents
- ea0200797-8k_immucell.htm (8-K) — 26KB
- ea0200797ex99-1_immucell.htm (EX-99.1) — 57KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-017520.txt ( ) — 265KB
- iccc-20240227.xsd (EX-101.SCH) — 3KB
- iccc-20240227_lab.xml (EX-101.LAB) — 33KB
- iccc-20240227_pre.xml (EX-101.PRE) — 22KB
- ea0200797-8k_immucell_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On February 27, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated February 27, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: February 27, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated February 27, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) 3